Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    HomeMedication GuideLarazotide Acetate safety
    Tight junction peptide modulator — research compoundInvestigational / Not FDA-Approved

    Larazotide: Patient Information & Safety Notes

    Also known as AT-1001

    Other names: at-1001

    Larazotide acetate is a synthetic 8-amino-acid peptide that acts as a tight junction regulator, reducing intestinal permeability ("leaky gut"). It has been studied in Phase 2 and Phase 3 clinical trials for celiac disease but has not received FDA approval.

    NOT FDA-approved. Larazotide has been studied in clinical trials for celiac disease, but a Phase 3 trial did not meet its primary endpoint. No therapeutic use has been approved.
    Reviewed by the OmniRx Health clinical teamLast reviewed Jul 4, 2026

    In plain language

    What Larazotide Acetate is used for

    • Investigated in clinical trials for celiac disease and intestinal permeability

    Taking this medicine

    How it is administered

    • Oral capsule

    Read before you decide

    Risks and precautions

    Risks and warnings

    • Nausea, headaches, abdominal discomfort, mild cramping (reported in clinical trials)
    • Clinical benefit not established — Phase 3 trial did not meet its primary endpoint

    Who should not take it

    • Safety not established in severe renal or hepatic impairment
    • Pregnancy or breastfeeding (insufficient safety data)

    Common questions

    Patient questions

    Is larazotide approved for celiac disease?

    No. Larazotide acetate has been studied in clinical trials for celiac disease but has not been FDA-approved. A Phase 3 trial did not meet its primary endpoint. Individuals with celiac disease should follow a gluten-free diet and work with a gastroenterologist for evidence-based management.

    Is larazotide the same as a gluten blocker?

    No. Larazotide does not block gluten digestion. It was studied as a tight junction modulator intended to reduce intestinal permeability associated with celiac disease. It is not an approved treatment and should not replace gluten avoidance.

    Explore treatment hubs

    This information is educational — not medical advice.

    This page is provided for general educational purposes and summarizes publicly available data from sources such as the U.S. Food & Drug Administration. It is not a substitute for the judgment of a licensed clinician and should not be used to start, stop, or change any medication. It may be incomplete or out of date, and individual circumstances vary. Always talk with your prescriber or pharmacist about your specific medications and health conditions. If you think you may have a medical emergency, call 911.